At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SBP GROUP
Not Yet Opened 08-26 16:08:03
5.735
+0.120
+2.14%
High5.915Low5.700Vol180.49M
Open5.740D1 Closing5.615Amplitude3.83%
Mkt Cap107.15BTradable Cap107.15BTotal Shares18.68B
T/O1.04BT/O Rate0.97%Tradable Shares18.68B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval
Deep News  ·  08-26 21:00
China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval
Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-26 16:32
Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
Movement Alert｜SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval
Market Focus  ·  08-26 09:47
Movement Alert｜SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval
Sino Biopharma Wins FDA Clearance to Start Trial of Cpx301 GLP-1 Weight-Loss Microneedle Patch
Reuters  ·  08-25 12:11
Sino Biopharma Wins FDA Clearance to Start Trial of Cpx301 GLP-1 Weight-Loss Microneedle Patch
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$8.26, Keeps at Buy
MT Newswires Live  ·  08-24 19:11
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$8.26, Keeps at Buy
Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest
Simply Wall St.  ·  08-22
Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest
Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook
Reuters  ·  08-22
Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook
SBP Group's Novel Weight Management Therapy Gains Regulatory Nod for Clinical Trials
Stock News  ·  08-21
SBP Group's Novel Weight Management Therapy Gains Regulatory Nod for Clinical Trials
Sino Biopharm Says NMPA Clears Tqf6422 Obesity Drug Candidate for Clinical Trial
Reuters  ·  08-21
Sino Biopharm Says NMPA Clears Tqf6422 Obesity Drug Candidate for Clinical Trial
Sino Biopharmaceutical - Application for Clinical Trial on Tqf6422 Injection "Actrii a/B Monoclonal Antibody" Approved by Nmpa
THOMSON REUTERS  ·  08-21
Sino Biopharmaceutical - Application for Clinical Trial on Tqf6422 Injection "Actrii a/B Monoclonal Antibody" Approved by Nmpa
Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades
Market Focus  ·  08-21
Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades
Sino Biopharmaceutical (SEHK:1177) Stock Faces Margin Strain Despite Profit Recovery
Simply Wall St.  ·  08-21
Sino Biopharmaceutical (SEHK:1177) Stock Faces Margin Strain Despite Profit Recovery
China's 3SBio H1 Net Profit Falls on Higher Expenses
Reuters  ·  08-20
China's 3SBio H1 Net Profit Falls on Higher Expenses
Chinese Medical Device Maker Zylox-Tonbridge's Revenue Rises 31%, Aided by Global Expansion
Reuters  ·  08-20
Chinese Medical Device Maker Zylox-Tonbridge's Revenue Rises 31%, Aided by Global Expansion
Hong Kong Stocks Close Higher: Vaccine Sector Surges on Historic mRNA Cancer Trial Breakthrough, Gold Miners Rally Again
Stock News  ·  08-20
Hong Kong Stocks Close Higher: Vaccine Sector Surges on Historic mRNA Cancer Trial Breakthrough, Gold Miners Rally Again
Sino Biopharmaceutical Stock Climbs 13% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-20
Sino Biopharmaceutical Stock Climbs 13% in Hong Kong, Outperforms Competitors
Citi Lifts SBP GROUP Price Target to HK$10.8, Citing Strong H1 Beat
Stock News  ·  08-20
Citi Lifts SBP GROUP Price Target to HK$10.8, Citing Strong H1 Beat
Finland's Nanoform Q2 Ebitda Loss Narrows on Layoffs, Cost Cuts
Reuters  ·  08-20
Finland's Nanoform Q2 Ebitda Loss Narrows on Layoffs, Cost Cuts
Movement Alert｜SBP GROUP Rises 10.33% in Regular Trading, H1 Earnings Beat Expectations with Revenue Hitting Record High
Market Focus  ·  08-20
Movement Alert｜SBP GROUP Rises 10.33% in Regular Trading, H1 Earnings Beat Expectations with Revenue Hitting Record High
Hong Kong Stock Market Update: SBP GROUP Jumps Over 6% After Results, H1 Revenue Hits Record 19.44 Billion Yuan, Gaining Endorsements From Top Global Pharmaceutical Firms
Stock News  ·  08-20
Hong Kong Stock Market Update: SBP GROUP Jumps Over 6% After Results, H1 Revenue Hits Record 19.44 Billion Yuan, Gaining Endorsements From Top Global Pharmaceutical Firms

Introduction

Company Name.
SBP GROUP
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
Issue price:
--